Gynaecomastia (benign glandular breast enlargement in males)
gonadal · Endocrine
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Benign proliferation of male breast glandular tissue from a relative increase in oestrogen:androgen action. Physiological (neonatal, pubertal, elderly) or pathological: drugs (spironolactone, cimetidine, antiandrogens, antipsychotics, cannabis, anabolic steroids), hypogonadism, hyperthyroidism, liver/renal disease, refeeding, and (rarely) oestrogen/hCG-secreting tumours. Must be distinguished from pseudogynaecomastia (fat) and breast cancer.
Red flags
- Hard, fixed, eccentric mass; nipple retraction/discharge/bleeding; skin change; axillary nodes — suspect male breast cancer
- Testicular mass or raised beta-hCG — germ-cell/oestrogen-secreting tumour
- Rapidly enlarging or markedly asymmetrical breast tissue
- Associated weight loss / systemic features
Assessment
Differential diagnosis
- Pseudogynaecomastia (adipose tissue, no firm subareolar disc)
- Male breast cancer (hard, eccentric, fixed, nipple change, lymphadenopathy — unilateral)
- Lipoma, dermoid, abscess/mastitis
- Drug-induced (very common — review every medication)
- Underlying hypogonadism, hyperthyroidism, chronic liver/renal disease
- hCG- or oestrogen-secreting tumour (testicular, adrenal, lung)
Investigations
- Clinical exam: concentric firm rubbery subareolar disc (gynaecomastia) vs eccentric hard mass (?cancer); examine testes
- If pathological features/rapid onset: testosterone, LH, FSH, oestradiol, prolactin, hCG (beta-hCG), TSH/free T4
- LFTs, U&E/eGFR (liver/renal cause), review drug history thoroughly
- If beta-hCG raised or testicular mass: testicular ultrasound +/- imaging for germ-cell/other tumour
- Mammography/ultrasound +/- biopsy if suspicious for malignancy
- Consider karyotype if hypogonadism with small firm testes (Klinefelter — increased breast cancer risk)
Management
- Confirm true gynaecomastia vs pseudogynaecomastia vs cancer on examination
- Review and stop/switch causative drugs where possible, then reassess
- Identify and treat underlying cause (hypogonadism, thyrotoxicosis, liver/renal disease, tumour)
- Reassure for physiological/pubertal cases — most resolve within 1-2 years; observe
- Painful recent (<12 months, proliferative) gynaecomastia may respond to a trial of tamoxifen
- Longstanding fibrotic gynaecomastia and cosmetic concern → surgical referral (it will not regress medically)
- Urgent breast referral for any features suggesting malignancy
Drugs & doses
No drug for physiological/pubertal gynaecomastia — reassure and observe
Tamoxifen 10-20 mg PO od for 3-6 months — for painful, recent, proliferative gynaecomastia [off-label, verify local]
Treat the cause: testosterone replacement if hypogonadal (see hypogonadism entry); antithyroid therapy if thyrotoxic
Stop/substitute culprit drug (e.g. switch spironolactone to eplerenone) where clinically possible
Disposition
Outpatient. Reassure/observe physiological cases. Urgent breast clinic for suspicious features; endocrine workup and surgical referral as indicated. Not an acute ED condition.
Complications & pitfalls
- Psychological distress
- Missed male breast cancer or testicular tumour if not examined
- Fibrosis making longstanding gynaecomastia irreversible to medical therapy
Exam pearls
- Always examine the testes and review the full drug list — drugs and hypogonadism are the common reversible causes.
- A firm concentric subareolar disc is benign gynaecomastia; a hard eccentric fixed mass needs urgent cancer workup.
- Pubertal gynaecomastia usually resolves spontaneously within 1-2 years — reassure and avoid over-investigation.
- Medical therapy (tamoxifen) only helps early proliferative/painful disease; fibrotic longstanding tissue needs surgery.
- Check beta-hCG and oestradiol if rapid onset in an adult to exclude a hormone-secreting tumour.
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.